Paper Details

  1. Home
  2. Paper Details

Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma.

Author: BahlisNizar J, ChenChristine, Del ColAldo, GasparettoCristina, JehaJacqueline, KauffmanMichael, KotbRami, LentzschSuzanne, NeriPaola, ReeceDonna, Saint-MartinJean-Richard, SebagMichael, ShachamSharon, ShahJatin, SutherlandHeather, UngerT J, VennerChristopher P, WhiteDarrell

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Selinexor in combination with low-dose bortezomib and dexamethasone showed high response rates in patients with relapsed or refractory multiple myeloma, including those refractory to bortezomib, with a recommended dose of selinexor 100 mg once weekly.
Paper Details　
Original Abstract of the Article :
Selinexor is an oral inhibitor of the nuclear export protein exportin 1. Preclinical studies demonstrated synergistic antimyeloma activity between selinexor and proteasome inhibitors (PI) through suppression of NF-κB signaling and nuclear retention of tumor suppressor proteins. We tested seline...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6302280/

データ提供：米国国立医学図書館（NLM）

Antibiotic-Resistant E. coli in Uncomplicated Community-Acquired Urinary Tract Infection

My dear readers, we venture into the world of infectious diseases, exploring the critical issue of antibiotic resistance in E. coli, a common cause of urinary tract infections (UTIs). This study investigated the sensitivity of E. coli to trimethoprim (TMP) and cotrimoxazole (TMP/SMX) in uncomplicated community-acquired UTIs. Imagine this as a battle against a relentless desert storm, where antibiotic resistance poses a growing threat to our ability to treat infections effectively.

Resistance Patterns and the Need for Vigilance

The study revealed that resistance patterns of E. coli to TMP and TMP/SMX varied significantly from those reported in the Antimicrobial Resistance Surveillance System (ARS). This is like a shifting desert landscape, where resistance patterns evolve over time, demanding a vigilant approach to antimicrobial stewardship. The researchers emphasized the importance of routine urine culture testing, even in uncomplicated UTIs, to accurately monitor resistance patterns and guide appropriate antibiotic selection.

The Importance of Culture Testing and Antimicrobial Stewardship

The study highlighted the critical need for continued monitoring of antibiotic resistance patterns to ensure effective treatment of UTIs. This is like a watchful desert traveler, constantly monitoring the environment for changes that could impact their journey. The findings underscore the importance of responsible antibiotic use, preventing the spread of resistant organisms and preserving the effectiveness of these vital medications.

Dr. Camel's Conclusion

This study serves as a stark reminder of the ever-evolving nature of antibiotic resistance, urging us to remain vigilant in our efforts to monitor resistance patterns and promote responsible antibiotic use. Remember, my dear readers, just as a skilled desert guide navigates a treacherous landscape, so too must we navigate the complexities of antibiotic resistance with careful observation and strategic action.
Date :
  1. Date Completed 2019-07-16
  2. Date Revised 2021-02-02
Further Info :

Pubmed ID

30352784

DOI: Digital Object Identifier

PMC6302280

Related Literature

Article Analysis
・Side Effects of selinexor
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.